Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...
- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna -
Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.
Gossamer Bio (NASDAQ:GOSS) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.16 by...
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary art...
Oppenheimer analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announce...
